肾素抑制剂阿利吉仑在高血压治疗中的应用进展  

Research Progress on Renin Inhibitor Aliskiren in the Treatment for Hypertension

作　　者：李素娟[1] 郭建强[2] 

机构地区：[1]内蒙古医科大学附属医院消化内科,呼和浩特010050 [2]内蒙古医科大学附属医院心血管内科,呼和浩特010050

出　　处：《医学综述》2015年第7期1250-1252,共3页Medical Recapitulate

摘　　要：肾素-血管紧张素-醛固酮系统在血压调控中发挥关键作用,阿利吉仑是一种非肽类可口服的直接肾素抑制剂,作用于肾素-血管紧张素-醛固酮系统的始动环节,降低肾素活性,减少血管紧张素Ⅱ和醛固酮的生成,从而发挥降压作用。大量循证医学证据表明,无论是单独使用还是与其他降压药物联合使用,阿利吉仑均能有效地降低血压,耐受性和安全性良好,且阿利吉仑对高血压靶器官损伤也有良好的保护作用,是一种理想的新型降压药物。The renin-angiotensin-aldosterone system（RAAS） has long been established as a key pathway in the regulation of blood pressure.Aliskiren is an oral non-peptidic direct renin inhibitor and is a novel blood pressure-lowering agent by blocking the first step of RAAS and reducing the formation of angiotensin Ⅱand aldosterone.A lot of studies have shown that whether used alone or in combination with other antihypertensive drugs,aliskiren can effectively lower blood pressure and has an ideal tolerability and safety.In addition to lowering blood pressure,aliskiren also has beneficial effect on hypertensive target organ protection and is an ideal new antihypertensive drugs.

关 键 词：高血压 阿利吉仑 肾素抑制剂 

分 类 号：R34[医药卫生—基础医学]